Participants in Nigeria Vaccinated in First-Ever Phase 2 Lassa Fever Vaccine Clinical Trial, Sponsored by IAVI
April 4, 2024
The CEPI-funded study will evaluate the safety, tolerability, and immunogenicity of IAVI’s single dose Lassa fever vaccine candidateKey takeaways:Participants in Nigeria have been vaccinated with